{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:31:12Z","timestamp":1788985872776,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction and Hypothesis<\/jats:title>\n            <jats:p>Overactive bladder (OAB) affects 11\u201317% of the female population. First-line treatment with lifestyle modifications and second-line therapy with medications are often limited by inadequate efficacy or pharmacological side effects. This study was aimed at assessing the effect of 100 U onabotulinumtoxin A treatment on idiopathic OAB (iOAB) as a second-line treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective follow-up study involved 94 women who received onabotulinumtoxin A treatment at a dose of 100 U as a second-line treatment for iOAB at the Department of Obstetrics and Gynecology, Oulu University Hospital, Finland, between May 2018 and December 2023. The impact of the treatment on iOAB symptoms was evaluated 3 months after administration using self-reported symptoms and the following internationally validated questionnaires: Visual Analogue Scale (VAS), Incontinence Impact Questionnaire (IIQ-7), and Urogenital Distress Inventory (UDI-6). Postoperative complications were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The follow-up data were obtained from 74 (78%) patients, of whom 66 (95.7%) reported a good outcome and 3 (4.3%) reported a poor outcome. Incontinence episodes, the number of incontinence pads needed, and daily micturitions were significantly reduced. For all questionnaires, the total scores decreased significantly after the treatment (VAS 8.27\u2009\u00b1\u20091.78 vs 3.50\u2009\u00b1\u20093.08, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; IIQ-7 72.14\u2009\u00b1\u200920.55 vs 28.73\u2009\u00b1\u200929.40, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; UDI-6 55.01\u2009\u00b1\u200918.86 vs 29.66\u2009\u00b1\u200922.03, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Postoperative urinary tract infection occurred in 9 patients (9.6%), whereas urinary retention occurred in 6 patients (6.4%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Onabotulinumtoxin A (100 U) demonstrates good effectiveness in the second-line treatment of female iOAB.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00192-025-06047-8","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:43:16Z","timestamp":1738334596000},"page":"685-693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of 100-U Onabotulinumtoxin A Treatment in Female Idiopathic Overactive Bladder\u2014A Prospective Follow-Up Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Mona","family":"Nurkkala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heini","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Piltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Sova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henna-Riikka","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"6047_CR1","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1097\/J.PBJ.0000000000000164","volume":"7","author":"P Abreu-Mendes","year":"2022","unstructured":"Abreu-Mendes P, Portugal-Rodrigues I, Vale L, Dinis P, Cruz F, Antunes-Lopes T, et al. Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients\u2019 expectations. Porto Biomed J. 2022;7:e164. https:\/\/doi.org\/10.1097\/J.PBJ.0000000000000164.","journal-title":"Porto Biomed J"},{"key":"6047_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/SPV.0B013E31822F816F","volume":"17","author":"AE Gousse","year":"2011","unstructured":"Gousse AE, Kanagarajah P, Ayyathurai R, Handa P, Dabas N, Gomez CS. Repeat intradetrusor injections of onabotulinum toxin A for refractory idiopathic overactive bladder patients: a single-center experience. Female Pelvic Med Reconstr Surg. 2011;17:253\u20137. https:\/\/doi.org\/10.1097\/SPV.0B013E31822F816F.","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"6047_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/S00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, De Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5\u201326. https:\/\/doi.org\/10.1007\/S00192-009-0976-9.","journal-title":"Int Urogynecol J"},{"key":"6047_CR4","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","volume":"197","author":"VW Nitti","year":"2017","unstructured":"Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197:S216\u201323. https:\/\/doi.org\/10.1016\/j.juro.2016.10.109.","journal-title":"J Urol"},{"key":"6047_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/J.1464-410X.2010.09993.X","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132\u20138. https:\/\/doi.org\/10.1111\/J.1464-410X.2010.09993.X.","journal-title":"BJU Int"},{"key":"6047_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/JOG.14708","volume":"47","author":"VW Nitti","year":"2021","unstructured":"Nitti VW, Patel A, Karram M. Diagnosis and management of overactive bladder: a review. J Obstet Gynaecol Res. 2021;47:1654\u201365. https:\/\/doi.org\/10.1111\/JOG.14708.","journal-title":"J Obstet Gynaecol Res"},{"key":"6047_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/j.1464-410X.2010.10013.x","volume":"108","author":"KS Coyne","year":"2011","unstructured":"Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108:1459\u201371. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.10013.x.","journal-title":"BJU Int"},{"key":"6047_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/TOXINS8030059","volume":"8","author":"PF Hsieh","year":"2016","unstructured":"Hsieh PF, Chiu HC, Chen KC, Chang CH, Chou ECL. Botulinum toxin A for the treatment of overactive bladder. Toxins (Basel). 2016;8:59. https:\/\/doi.org\/10.3390\/TOXINS8030059.","journal-title":"Toxins (Basel)"},{"key":"6047_CR9","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1001\/JAMA.2017.12137","volume":"318","author":"ES Lukacz","year":"2017","unstructured":"Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women a review. JAMA. 2017;318:1592\u2013604. https:\/\/doi.org\/10.1001\/JAMA.2017.12137.","journal-title":"JAMA"},{"key":"6047_CR10","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/NAU.25532","volume":"43","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, Enemchukwu E, Ginsberg DA, Helfand BT, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. Neurourol Urodyn. 2024;43:1742\u201352. https:\/\/doi.org\/10.1002\/NAU.25532.","journal-title":"Neurourol Urodyn"},{"key":"6047_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/IJCP.12360","volume":"68","author":"G Karsenty","year":"2014","unstructured":"Karsenty G, Baverstock R, Carlson K, Diaz DC, Cruz F, Dmochowski R, et al. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract. 2014;68:731\u201342. https:\/\/doi.org\/10.1111\/IJCP.12360.","journal-title":"Int J Clin Pract"},{"key":"6047_CR12","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/S11255-015-1125-7","volume":"47","author":"Y Sun","year":"2015","unstructured":"Sun Y, Luo D, Tang C, Yang L, Shen H. The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47:1779\u201388. https:\/\/doi.org\/10.1007\/S11255-015-1125-7.","journal-title":"Int Urol Nephrol"},{"key":"6047_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/SPV.0000000000000277","volume":"22","author":"AG Visco","year":"2016","unstructured":"Visco AG, Zyczynski H, Brubaker L, Nygaard I, Xu X, Lukacz ES, et al. Cost-effectiveness analysis of anticholinergics versus botox for urgency urinary incontinence: results from the anticholinergic versus botox comparison randomized trial. Female Pelvic Med Reconstr Surg. 2016;22:311\u20136. https:\/\/doi.org\/10.1097\/SPV.0000000000000277.","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"6047_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/S00192-018-3653-Z\/TABLES\/4","volume":"29","author":"JP Shepherd","year":"2018","unstructured":"Shepherd JP, Carter-Brooks CM, Chermanksy C. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder. Int Urogynecol J. 2018;29:1213\u20139. https:\/\/doi.org\/10.1007\/S00192-018-3653-Z\/TABLES\/4.","journal-title":"Int Urogynecol J"},{"key":"6047_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/J.EURURO.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, Macdiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249\u201356. https:\/\/doi.org\/10.1016\/J.EURURO.2013.04.001.","journal-title":"Eur Urol"},{"key":"6047_CR16","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.4111\/ICU.2020.61.S1.S33","volume":"61","author":"JL Chen","year":"2020","unstructured":"Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61:S33. https:\/\/doi.org\/10.4111\/ICU.2020.61.S1.S33.","journal-title":"Investig Clin Urol"},{"key":"6047_CR17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/NAU.23170","volume":"36","author":"A Apostolidis","year":"2017","unstructured":"Apostolidis A, Averbeck MA, Sahai A, Rahmana\u2019i S, Anding R, Robinson D, et al. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36:882\u201393. https:\/\/doi.org\/10.1002\/NAU.23170.","journal-title":"Neurourol Urodyn"},{"key":"6047_CR18","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1002\/NAU.24055","volume":"38","author":"C Chermansky","year":"2019","unstructured":"Chermansky C, Schurch B, Rahnama\u2019i MS, Averbeck MA, Malde S, Mancini V, et al. How can we better manage drug-resistant OAB\/DO? ICI-RS 2018. Neurourol Urodyn 2019;38:S46\u201355. https:\/\/doi.org\/10.1002\/NAU.24055.","journal-title":"Neurourol Urodyn"},{"key":"6047_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/J.EUF.2018.05.004","volume":"4","author":"T Marcelissen","year":"2018","unstructured":"Marcelissen T, Cornu JN, Antunes-Lopes T, Geavlete B, Delongchamps NB, Rashid T, et al. Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment? Eur Urol Focus. 2018;4:760\u20137. https:\/\/doi.org\/10.1016\/J.EUF.2018.05.004.","journal-title":"Eur Urol Focus"},{"key":"6047_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/J.GTC.2021.10.010","volume":"51","author":"ER Trowbridge","year":"2022","unstructured":"Trowbridge ER, Hoover EF. Evaluation and treatment of urinary incontinence in women. Gastroenterol Clin North Am. 2022;51:157\u201375. https:\/\/doi.org\/10.1016\/J.GTC.2021.10.010.","journal-title":"Gastroenterol Clin North Am"},{"key":"6047_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5603\/GP.A2022.0105","volume":"94","author":"A Licow","year":"2022","unstructured":"Licow A, Ciecwiez S, Brodowska A. Quality of life in patients with overactive bladder following botulinum toxin treatment: a preliminary report. Ginekol Pol. 2022;94:593\u20138. https:\/\/doi.org\/10.5603\/GP.A2022.0105.","journal-title":"Ginekol Pol"},{"key":"6047_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/003655901753367587","volume":"35","author":"B Stach-Lempinen","year":"2001","unstructured":"Stach-Lempinen B, Kujansuu E, Laippala P, Mets\u00e4noja R. Visual analogue scale, urinary incontinence severity score and 15 D\u2014psychometric testing of three different health-related quality-of-life instruments for urinary incontinent women. Scand J Urol Nephrol. 2001;35:476\u201383. https:\/\/doi.org\/10.1080\/003655901753367587.","journal-title":"Scand J Urol Nephrol"},{"key":"6047_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/00016348209156544","volume":"61","author":"A Kauppila","year":"1982","unstructured":"Kauppila A, Alavaikko P, Kujansuu E. Detrusor instability score in the evaluation of stress urinary incontinence. Acta Obstet Gynecol Scand. 1982;61:137\u201341. https:\/\/doi.org\/10.3109\/00016348209156544.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"6047_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/NAU.1930140206","volume":"14","author":"JS Uebersax","year":"1995","unstructured":"Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Andrew FJ. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Neurourol Urodyn. 1995;14:131\u20139. https:\/\/doi.org\/10.1002\/NAU.1930140206.","journal-title":"Neurourol Urodyn"},{"key":"6047_CR25","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/S00192-023-05527-Z","volume":"34","author":"H Salo","year":"2023","unstructured":"Salo H, Sova H, Laru J, Talvensaari-Mattila A, Nyyss\u00f6nen V, Santala M, et al. Long-term results of a prospective randomized trial comparing tension-free vaginal tape versus transobturator tape in stress urinary incontinence. Int Urogynecol J. 2023;34:2249\u201356. https:\/\/doi.org\/10.1007\/S00192-023-05527-Z.","journal-title":"Int Urogynecol J"},{"key":"6047_CR26","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/JAMA.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. Onabotulinumtoxin a vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316:1366\u201374. https:\/\/doi.org\/10.1001\/JAMA.2016.14617.","journal-title":"JAMA"},{"key":"6047_CR27","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/J.JURO.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186\u201393. https:\/\/doi.org\/10.1016\/J.JURO.2012.12.022.","journal-title":"J Urol"},{"key":"6047_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","volume":"176","author":"DM Schmid","year":"2006","unstructured":"Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177\u201385. https:\/\/doi.org\/10.1016\/S0022-5347(06)00590-8.","journal-title":"J Urol"},{"key":"6047_CR29","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/01.JU.0000169481.42259.54","volume":"174","author":"A Apostolidis","year":"2005","unstructured":"Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford APDW, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977\u201383. https:\/\/doi.org\/10.1097\/01.JU.0000169481.42259.54.","journal-title":"J Urol"},{"key":"6047_CR30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/J.EURURO.2019.02.038","volume":"75","author":"B Peyronnet","year":"2019","unstructured":"Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75:988\u20131000. https:\/\/doi.org\/10.1016\/J.EURURO.2019.02.038.","journal-title":"Eur Urol"},{"key":"6047_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/S00192-022-05127-3\/METRICS","volume":"33","author":"C Sze","year":"2022","unstructured":"Sze C, Pressler M, Lee JR, Chughtai B. The gut, vaginal, and urine microbiome in overactive bladder: a systematic review. Int Urogynecol J. 2022;33:1157\u201364. https:\/\/doi.org\/10.1007\/S00192-022-05127-3\/METRICS.","journal-title":"Int Urogynecol J"},{"key":"6047_CR32","unstructured":"Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results n.d. https:\/\/www.europeanreview.org\/article\/11002. Accessed 17 Nov 2024."},{"key":"6047_CR33","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/S00192-022-05127-3\/METRICS","volume":"13","author":"K Du","year":"2024","unstructured":"Du K, Sun X, Yang F, Qiu Z, Li L, Zhao Y, et al. Evaluation of transurethral GreenLight laser-selective vaporization for refractory overactive bladder in women. Transl Androl Urol. 2024;13:1164\u201372. https:\/\/doi.org\/10.21037\/TAU-24-67\/PRF.","journal-title":"Transl Androl Urol"},{"key":"6047_CR34","unstructured":"Virtsankarkailu (naiset). K\u00e4yp\u00e4 hoito -suositus. Suomalaisen L\u00e4\u00e4k\u00e4riseuran Duodecimin ja Suomen Gynekologiyhdistyksen asettama ty\u00f6ryhm\u00e4. Helsinki: Suomalainen L\u00e4\u00e4k\u00e4riseura Duodecim, 2017. Available at: www.kaypahoito.fi. Accessed 13 Nov 2024."}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06047-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-025-06047-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06047-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:33:07Z","timestamp":1744810387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-025-06047-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6047"],"URL":"https:\/\/doi.org\/10.1007\/s00192-025-06047-8","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the hospital district of Northern Ostrobothnia, Finland (124\/2020). No ethical approval was required for this register-based study as the patients received treatment according to standard medical practice and all questionnaires used were part of routine protocol for assessing the efficacy of treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}